BioSpace News Archive

Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that real world data on Endari®, the company’s prescription-grade L-glutamine oral powder for the treatment of sickle cell disease, has been accepted for an e-poster at the 62nd Annual Meeting of the British Society for Haematology.

Berkeley Lights, Inc., a leader in digital cell biology, announced its participation at the upcoming Festival of Biologics meeting, being held from March 9-11, 2022, at the Marriott Marquis San Diego.

PolyActiva Pty Ltd, today announced that data from the Phase IIa study of its PA5108 Ocular Implant for the treatment of Primary Open-Angle Glaucoma (POAG) will be presented at the 2022 American Glaucoma Society (AGS) Annual Meeting.

Altamira Therapeutics Ltd. announced that it has entered into an exclusive licensing and distribution agreement for Bentrio™, its nasal spray for protection against airborne viruses and allergens, with Nuance Pharma Ltd. in Chinese Mainland, Hong Kong, Macau and South Korea.

Albany NY, United States: Mammography is the diagnostic evaluation of breast tissues to detect the presence of carcinogenic cells.

The pulse generator sends electricity to the nerve fibres in the spinal cord through a small cable.

Core One Labs Inc. is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“ Akome ”), has entered into an agreement with the Universidad Complutense de Madrid (“Universidad Complutense”) to advance the development of the Company’s patent pending psychedelic bioactive compounds that target Alzheimer’s Disease, Parkinson’s Disease, Major Depressive Disorder and Ischemic Stroke.

Vicore Pharma Holding AB, a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor, will host a virtual R&D Day with a focus on its primary drug development programs and this new class of medicine, AT2R agonists, on Thursday, March 10, 2022, from 15:00-17:00 CET/9-11 AM EST.

American CryoStem Corporation a clinical stage biotechnology company, global licensor, and a pioneer in autologous cellular processing and cellular therapies, announced that it has reached the midway point of its ATCell™ autologous mesenchymal stem cell therapy for Phase I Clinical Trial for Post-concussion syndrome.

Boston Scientific Corporation has priced a public offering of €1,000,000,000 aggregate principal amount of 0.750% notes due 2025.